Scopio Labs is redefining the future of hematology diagnostics with the unveiling of its revolutionary Complete Blood Morphology (CBM®) analyzer-marking the world’s first fully automated solution for blood cell morphology analysis. Traditionally, peripheral blood smear (PBS) reviews have remained largely manual, even as other parts of hematology diagnostics, such as Complete Blood Counts (CBCs), have long been automated. This manual dependency has led to inefficiencies, delays, and variability in diagnostic results—problems that are further compounded by global shortages in skilled lab personnel. Scopio’s CBM® solution is designed to fill this long-standing automation gap, offering a transformative leap toward faster, standardized, and highly scalable diagnostic workflows.

At the core of the CBM® analyzer is Scopio’s proprietary Full-Field technology, which uses advanced computational imaging and AI-driven analysis to examine blood smears with unprecedented depth and precision. By analyzing 10 times more cells than the current standard of care, the system not only enhances diagnostic accuracy but also enables the full automation of morphology reviews-freeing labs from the burdens of manual processes. This innovation addresses critical bottlenecks in hematology labs and supports broader goals of efficiency, consistency, and improved patient outcomes. The addition of a $10 million Series D extension led by Viola Growth underscores strong investor confidence in the platform’s potential and accelerates its path to market.

Looking ahead, CBM® holds the promise of transforming hematology from a fragmented, human-dependent workflow into a fully integrated and automated continuum-from CBC to final diagnosis. This positions Scopio Labs not only as a technology provider but as a pioneer of a new market category in diagnostics. As CBM® adoption scales, it could enable the development of next-generation morphology-based biomarkers and diagnostics for early disease detection directly from blood-opening new frontiers in personalized medicine. In a time when healthcare systems are under increasing pressure to deliver more with less, Scopio’s innovation stands as a beacon of what’s possible when imaging, AI, and clinical need converge.